NEW YORK (GenomeWeb News) – Investment bank Cantor Fitzgerald today initiated coverage of Cancer Genetics with a Buy rating and a $21 price target on its shares.

In a research note, analyst Sung Ji Nam said that challenges await companies developing and commercializing genomic tests, but Rutherford, NJ-based Cancer Genetics has strengths in leveraging clinical development collaborations with leading healthcare partners. Additionally, Nam said, the company has one of the most comprehensive sets of diagnostic services targeting cancer types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.